Literature DB >> 10986355

TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease.

P Shashidharan1, P F Good, A Hsu, D P Perl, M F Brin, C W Olanow.   

Abstract

Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986355     DOI: 10.1016/s0006-8993(00)02702-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

2.  A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study.

Authors:  N Sharma; J Hewett; L J Ozelius; V Ramesh; P J McLean; X O Breakefield; B T Hyman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 3.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

4.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

Review 5.  Molecular chaperones and co-chaperones in Parkinson disease.

Authors:  Hemi Dimant; Darius Ebrahimi-Fakhari; Pamela J McLean
Journal:  Neuroscientist       Date:  2012-07-24       Impact factor: 7.519

Review 6.  Potential neuroprotective activity of Ginseng in Parkinson's disease: a review.

Authors:  Elena González-Burgos; Carlos Fernandez-Moriano; M Pilar Gómez-Serranillos
Journal:  J Neuroimmune Pharmacol       Date:  2014-10-29       Impact factor: 4.147

Review 7.  Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.

Authors:  Sandeep K Sharma; Smriti Priya
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

8.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

9.  Glial elements contribute to stress-induced torsinA expression in the CNS and peripheral nervous system.

Authors:  Y Zhao; J Xiao; M Ueda; Y Wang; M Hines; T S Nowak; M S LeDoux
Journal:  Neuroscience       Date:  2008-05-06       Impact factor: 3.590

Review 10.  The genetics of dystonias.

Authors:  Mark S LeDoux
Journal:  Adv Genet       Date:  2012       Impact factor: 1.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.